Cantor Fitzgerald reiterates Eli Lilly stock rating ahead of launch By Investing.com

FDA approved Foundayo (oral orforglipron) for obesity — a major product approval that is a clear positive catalyst for Eli Lilly. LLY trades at $931 versus InvestingPro Fair Value $1,024.64 and multiple analyst targets of $1,205 (Cantor Fitzgerald), $1,294 (BofA), $1,296 (Leerink) and $1,281 (Truist). Lilly reports earnings on April 30, 2026 with consensus full-year EPS of $34.57. Separately, AC Immune amended a collaboration with Lilly including a CHF10m upfront payment and >CHF1.7bn of potential milestones plus tiered royalties, adding material upside to long-term pipeline value.

Analysis

The core structural read is that an oral GLP-1 class entrant re-weights competitive dynamics from administration-mode competition (injectable devices, clinic throughput) toward distribution, payer formulary negotiation, and API/manufacturing scale. If orals can capture ~20–40% of incremental GLP-1 volume inside 12 months, incumbents with device-driven economics (and higher per-unit COGS) will see margin compression while pharmacy and PBM channels gain pricing leverage.

Second-order winners include specialty pharmacies, contract-manufacturing organizations focused on small-molecule API scale-up, and smaller biotech partners with sub-license or milestone exposure — these can rerate quickly on milestone realization. Conversely, clinic-centric weight-loss service providers and device consumable vendors face demand erosion; expect to see reduced referral volumes and downward pricing pressure on procedural margins within 6–12 months.

Key catalysts and risks are asymmetrical: payer coverage decisions and real-world capture rates can swing revenue trajectories by tens of percent inside the first two commercial quarters, while a safety or efficacy shortfall could reprice shares by 25–40% rapidly. Manufacturing hiccups or unexpected rebate/contract concessions from large PBMs create medium-term downside; longer term, combination therapies and geography-specific uptake will determine whether orals merely cannibalize existing GLP-1 sales or expand the total addressable market.

Key Decisions for Investors

• LLY directional (options): Buy a 3–6 month call spread to play commercial momentum (example sizing: 0.5–1% NAV). Target a 2.5–3x return if launch traction and favorable formulary headlines arrive; cap max loss to premium paid. Enter within the next 2–4 weeks and tighten if capture rates print below modeled 15% in the first quarter.
• LLY / NVO pair (equity): Long LLY (1% NAV) financed by short Novo Nordisk (0.6% NAV) — directional play on faster oral uptake and superior margin capture. Time horizon 6–12 months; stop-loss pair if LLY underperforms NVO by >15% over a 30-day window.
• ACIU asymmetric biotech: Small, size-constrained long position (0.25–0.75% NAV) or long-dated call to own binary milestone upside from the collaboration pathway. Expect high idiosyncratic volatility; treat as option on upstream licensing payments with >3x upside on successful milestones and 100% downside if they miss.
• Tail-hedge protection: Buy protective puts on LLY (3–6 month tenor, OTM) sized to cover 25–40% of equity exposure ahead of near-term commercial and payer milestones. This limits downside from safety/payer shocks that could cause a rapid re-rate while retaining upside participation.